<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02869971</url>
  </required_header>
  <id_info>
    <org_study_id>P150917</org_study_id>
    <secondary_id>PHRC-15-521</secondary_id>
    <secondary_id>2016-A00247-44</secondary_id>
    <nct_id>NCT02869971</nct_id>
  </id_info>
  <brief_title>Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia</brief_title>
  <acronym>PARTEM</acronym>
  <official_title>Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to compare the 9-month effect on lower urinary tract
      symptoms (LUTS) of Prostatic Artery Embolization (PAE) using Embosphere® versus Standard
      Combined Therapy (alpha-blockers plus 5 alpha-reductase inhibitors) in patients with
      symptomatic BPH who failed after a first line medical treatment with alpha-blockers.

      The secondary objectives of this study are to:

        -  Estimate the impact of the 2 strategies on benign prostatic hyperplasia specific Health
           Status (i.e. urinary and sexual signs and symptoms) at 3, 9, 18, and 24 months, as well
           as the side effects of the 2 strategies;

        -  Report the safety of PAE;

        -  Evaluate patient's adherence to medical treatment;

        -  Analyse the costs of each strategy and report the incremental efficiency (incremental
           cost utility ratio) of prostatic artery embolization compared to medical treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Benign Prostatic Hyperplasia (BPH) is the primary cause of lower urinary tract symptoms
      (LUTS) and affects &gt; 50% of men &gt;60 years. Moderate to severe symptoms prevalence is around
      14% in France, and the proportion of men with moderate to severe symptoms doubles with each
      decade of age. The first-line treatment of bothersome BPH-related LUTS is medical therapy as
      recommended by French and European guidelines. 5α reductase inhibitors (5-ARI) can be
      combined with alpha-blockers and allow reduction of the size of the prostate and LUTS
      improvement. The severity of symptoms is usually assessed using the International prostate
      symptom score (IPSS) which is the standard questionnaire for the objective assessment of
      LUTS.

      Recently, Prostatic Artery Embolization (PAE) has been proposed to treat symptomatic BPH with
      good safety and efficacy in single-centre studies (12-point IPSS reduction at 3 months
      maintained up to one year. In a randomized trial comparing PAE versus transurethral resection
      of prostate (TURP), Gao reported a 16-point IPSS reduction at 6 months, and an increase in
      the maximum urinary flow rate (Qmax) comprised between 12 ml/s and 24 ml/s at 6 months and up
      to 21 ml/s at 2 years. The complication rate is low (a few cases of bladder ulcer have been
      published) and the patient generally experiences mild post-embolization symptoms for few
      days.

      PAE can be performed during a one-day hospitalisation and could be very attractive to
      patients which have insufficient benefit of medical treatment or who have side effects
      affecting their quality of life. The most used device for PAE is Embosphere® (Merit Medical).
      It bears the European CE (Conforme aux Exigences) marking for this specific indication and
      approximately 500 patients have been treated with it worldwide. Nonetheless, no big
      randomized study has proven its efficacy compared with best medical treatment. A study
      comparing PAE using Embosphere® and surgery (TURP) is currently enrolling patients; no
      patients could be included in France because men with BPH refused to be potentially assigned
      the surgical arm.

      To properly evaluate PAE, the investigators designed the PARTEM trial, which has received the
      support of both the Societe Francaise de Radiologie (French society of radiology) and of the
      Association Francaise d'Urologie (French association of urology).

      PARTEM will compare prospectively the benefit of PAE using Embosphere® to the benefit of
      combined medical treatment (Combodart®: Dutasteride 0.5mg Tamsulosin 0.4mg) at 9 months with
      an extended follow up at 24 months in order to evaluate the stability of results in both
      groups.

      The investigators plan a multicentre, prospective, randomized, open label, parallel trial,
      comparing PAE to Combined Therapy (CT: alpha-blockers + 5-ARI treatment). Treatments will be
      allocated by minimization with a 1:1 ratio, based on study centre, IPSS score
      (moderate/severe) and prostate volume (&lt; 80 g/≥80 g).

      This study is designed to demonstrate the superiority of PAE to decrease LUTS compared to
      best medical treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in IPSS score</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>3, 9, 18, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS</measure>
    <time_frame>3, 18, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qmax</measure>
    <time_frame>3, 9, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF) score</measure>
    <time_frame>3, 9, 18, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prostate volume</measure>
    <time_frame>3, 9, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-Specific Antigen (PSA) level</measure>
    <time_frame>3, 9, 18, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>3, 9, 18, 24 months</time_frame>
    <description>assessed by IPSS/Quality of Life (QoL) form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment units' account</measure>
    <time_frame>3, 9 months</time_frame>
    <description>adherence to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment questionnaire</measure>
    <time_frame>3, 9 months</time_frame>
    <description>adherence to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of PAE</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of surgical treatment</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of medication</measure>
    <time_frame>3, 9, 18, 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prostatic Arteries Embolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combodart® : dutasteride 0.5 mg/tamsulosin 0.4 mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Embosphere® (Prostatic Arteries Embolization)</intervention_name>
    <description>Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres</description>
    <arm_group_label>Embolization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug therapy</intervention_name>
    <description>Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)</description>
    <arm_group_label>Combined Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged&gt;= 50 and &lt;=85 years AND

          -  Moderate to severe LUTS defined as IPSS &gt; 11, and QoL &gt; 3 and Qmax &lt; 15ml/sec AND

          -  No improvement after an alpha blocker treatment line (Tamsulosin 0.4 mg p.d. during 1
             month) AND

          -  Prostatic volume &gt;=50 ml AND

          -  Affiliated to a French health insurance system

        Exclusion Criteria:

          -  Severe allergy to iodine contrast agent

          -  Any previous treatment with 5-ARI

          -  Suspected prostate cancer requiring specific management

          -  On-going prostatitis

          -  On-going urinary retention

          -  On-going acute urinary infection

          -  Acontractile detrusor

          -  Neurogenic lower urinary tract dysfunction

          -  Urethral stenosis

          -  Bladder diverticulum

          -  Bladder stone with surgical indication

          -  Patient refusing PAE

          -  Creatinine clearance &lt;40 ml/min

          -  Severe liver failure

          -  Contra-indication to alpha-blockers

          -  Hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, tamsulosin
             (including case of tamsulosin induced angioedema), soya, peanut or one of the
             excipients

          -  Hypersensitivity to gelatin or collagen

          -  Patients ineligible for pelvic angiography

          -  History of orthostatic hypotension

          -  Patient unable or unwilling to provide written informed consent

          -  Patient under legal protection
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Sapoval, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Sapoval, MD</last_name>
    <email>marc.sapoval2@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Lyon hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <state>Auvergne-Rhone-Alpes</state>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaele Pagnoux, MD</last_name>
      <email>gaele.pagnoux@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon centre hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Benite</city>
        <state>Auvergne-Rhone-Alpes</state>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Ruffion, MD</last_name>
      <email>alain.ruffion@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Francois Heautot, MD</last_name>
      <email>heautot@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Francois Heautot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain Mathieu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier hopital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <state>Languedoc-Roussillon-Midi-Pyrenees</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helene Vernhet-Kovacsik, MD</last_name>
      <email>h-vernhet@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier hopital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <state>Languedoc-Roussillon-Midi-Pyrenees</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thibaut Muriez, MD</last_name>
      <email>t-muriez@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux groupe hospitalier Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <state>Nouvelle-Aquitaine</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Grenier, MD</last_name>
      <email>nicolas.grenier@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Grenier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregoire Robert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <state>Nouvelle-Aquitaine</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <state>Pays De La Loire</state>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Bouvier, MD</last_name>
      <email>anbouvier@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine Bouvier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Souhil Lebdai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM hopital la Conception</name>
      <address>
        <city>Marseille</city>
        <state>Provence-Alpes-Cote d'Azur</state>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Karsenty, MD</last_name>
      <email>gilles.karsenty@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HM hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <state>Provence-Alpes-Cote d'Azur</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Vidal, MD</last_name>
      <email>vincent.vidal@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP hopital Henri-Mondor</name>
      <address>
        <city>Creteil</city>
        <state>Île-de-France</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hicham Kobeiter, MD</last_name>
      <email>hicham.kobeiter@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Hicham Kobeiter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre de la Taille, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP hopital Cochin</name>
      <address>
        <city>Paris</city>
        <state>Île-de-France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Barry-Delongchamp, MD</last_name>
      <email>nicolas.barry-delongchamps@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <state>Île-de-France</state>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Sapoval, MD</last_name>
      <email>marc.sapoval2@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Sapoval, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Thiounn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatic artery embolization</keyword>
  <keyword>Combined Therapy</keyword>
  <keyword>IPSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

